Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
NCT02404389
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
82
Enrollment
INDUSTRY
Sponsor class
Conditions
Actinic Keratosis
Interventions
DRUG:
Investigational Treatment
DRUG:
Active comparator
Sponsor
Novartis Pharmaceuticals